Why Fresenius (FMS) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·5d ago
More News
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·13d ago
Reasons to Hold Fresenius Medical Stock in Your Portfolio for Now
FMS acquisitions, partnerships and global reach fuel growth, though rising costs weigh on near-term prospects.
Zacks·14d ago
Are Options Traders Betting on a Big Move in Fresenius Medical Stock?
Investors need to pay close attention to FMS stock based on the movements in the options market lately.
Zacks·27d ago
Encompass Health Q2 Earnings Beat Estimates, Stock Up 7.4%
EHC posts strong Q2 with higher EPS, revenue growth, and a raised 2025 outlook, along with shares gaining 7.4%.
Zacks·2mo ago
FMS vs. OFIX: Which Stock Should Value Investors Buy Now?
FMS vs. OFIX: Which Stock Is the Better Value Option?
Zacks·2mo ago
Select Medical Shares Down 20% Despite Q2 Earnings Beat
SEM beats Q2 EPS estimates on strong Rehab admissions and higher revenue per patient day. Yet, shares drop 20.4% post-earnings.
Zacks·2mo ago
FMS Stock Rises as Q2 Earnings Beat Estimates, Revenues Gain Y/Y
Fresenius Medical stock rises as Q2 earnings and revenues top estimates, driven by solid organic growth and expanding margins.
Zacks·2mo ago
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Zacks·2mo ago
Here's Why Fresenius (FMS) Looks Ripe for Bottom Fishing
Fresenius (FMS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.